Status:
COMPLETED
Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
Lead Sponsor:
Teres Bio, Inc.
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
12-65 years
Phase:
PHASE2
Brief Summary
This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic dermatitis.
Eligibility Criteria
Inclusion
- Adolescent or adult subject aged 12 - 65 years.
- Overall IGA score of 2 (mild) or 3 (moderate) at baseline on a 5-point IGA
Exclusion
- AD with known hypersensitivity to excipients of TER-101 Ointment
- Subjects who are immunocompromised
Key Trial Info
Start Date :
January 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 3 2021
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT04753034
Start Date
January 18 2021
End Date
May 3 2021
Last Update
July 26 2022
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Teres Bio site 05
Scottsdale, Arizona, United States, 85255
2
Teres Bio Site 04
Encinitas, California, United States, 92024
3
Teres Bio Site 12
North Miami Beach, Florida, United States, 33162
4
Teres Bio Site 10
Tampa, Florida, United States, 33613